EPS-3903 — IND submission
H2 2026
The Company is currently performing scale-up and IND enabling activities and is targeting an IND filing in the second half of 2026.Source filing
ENTA biotech catalysts & pipeline
ENANTA PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
EDP-978 — Topline data
Q4 2026
Additionally, in immunology, we are focused on reporting topline data from our Phase 1 study of EDP-978 in the fourth quarter of 2026, while also advancing EPS-3903, our oral, once-daily STAT6 inhibitor, toward an IND filing this year.Source filing
zelicapavir — Topline data
2027
Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027Source filing